These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 19417645

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Pharmacotherapy of inflammatory bowel disease].
    Jojić N.
    Acta Chir Iugosl; 2000; 47(1-2):51-5. PubMed ID: 10953366
    [Abstract] [Full Text] [Related]

  • 24. [Therapeutic principles for chronic inflammatory bowel disease].
    Binder V, Munkholm P.
    Ugeskr Laeger; 2001 Jan 01; 163(1):16-21. PubMed ID: 11586666
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
    Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L.
    Am J Gastroenterol; 2010 May 01; 105(5):1142-9. PubMed ID: 20389296
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Use of infliximab in particular clinical settings: management based on current evidence.
    Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A.
    Am J Gastroenterol; 2009 Jun 01; 104(6):1575-86. PubMed ID: 19491875
    [Abstract] [Full Text] [Related]

  • 30. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
    Van Assche G, Vermeire S, Rutgeerts P.
    Eur J Pharmacol; 2009 Nov 25; 623 Suppl 1():S17-25. PubMed ID: 19837056
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
    Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P.
    Gastroenterology; 2008 Jun 25; 134(7):1861-8. PubMed ID: 18440315
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Management of varicella infection during the course of inflammatory bowel disease.
    Mouzas IA, Greenstein AJ, Giannadaki E, Balasubramanian S, Manousos ON, Sachar DB.
    Am J Gastroenterol; 1997 Sep 25; 92(9):1534-7. PubMed ID: 9317080
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Maintenance of medically induced remission of Crohn's disease.
    Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F.
    Digestion; 2007 Sep 25; 76(2):116-29. PubMed ID: 18239403
    [Abstract] [Full Text] [Related]

  • 40. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2007 Sep 25; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.